WHOOP Is Worth $10bn. Garmin Is Worth $40bn. Really?

WHOOP has closed a $575 million Series G funding round at a $10.1 billion valuation, announced on 31 March 2026. That number deserves thought. Garmin generates approximately $7 billion in annual revenues across five business segments and carries a public market capitalisation of around $44 billion. WHOOP has a reported run rate of $1.1 billion, operates in a single product category, has never faced public-market pricing, and carries an outstanding FDA warning letter regarding its Blood Pressure Insights feature.

The $10.1 billion is a bet on a future health platform that has not yet arrived. WHOOP is currently a recovery and sleep tracker with a strong coaching app and 2.5 million members. The gap between that and what the valuation implies is considerable.

Further, those numbers imply a per customer valuation of $440 — almost certainly far above Garmin’s equivalent, though the subscription model justifies some of that premium.

The IPO Question

Earlier this year, WHOOP announced plans to hire more than 600 people in 2026, widely interpreted as a signal toward a public listing, and covered on this site. This Series G complicates that reading. Large private rounds at elevated valuations tend to delay listings rather than accelerate them, and there is no reason to expect WHOOP to be an exception.

A History of Funding

• July 2013: Seed, approximately $3.4 million. Backers include Collab Fund, Accomplice, and NextView Ventures.
• September 2015: Series B, backed by Two Sigma Ventures and Mousse Partners.
• March 2018: Series C. The NFL Players Association and Kevin Durant’s investment vehicle participate.
• November 2019: Series D, $55 million, led by Foundry Group. Covered on this site.
• October 2020: Series E, $100 million at a $1.2 billion valuation. Also covered here.
• August 2021: Series F, $200 million at a $3.6 billion valuation, led by SoftBank Vision Fund 2.
• March 2026: Series G, $575 million at $10.1 billion valuation, led by Collaborative Fund.

The Investor Composition

Interestingly, healthcare institutions feature prominently in the latest round of investors. Abbott, whose portfolio spans continuous glucose monitors and cardiac devices, joins as a strategic investor alongside Mayo Clinic. Any integration of Abbott’s diagnostic capabilities with WHOOP’s physiological data would extend the platform materially and represent the clearest route to justifying the valuation over time. Sovereign wealth participation comes from Qatar Investment Authority and Mubadala. Athlete investors include Cristiano Ronaldo, LeBron James, Rory McIlroy, Virgil van Dijk, and Mathieu van der Poel.

Quick answers

Is WHOOP overvalued at $10.1 billion?
On current revenues, yes. A run rate of $1.1 billion does not support a $10.1 billion valuation in isolation. The figure is a bet on WHOOP becoming a healthcare platform that integrates clinical diagnostics and preventive medicine, not a reflection of its current business.

When will WHOOP IPO?
No date has been announced. The March 2026 Series G complicates earlier expectations set by WHOOP’s 600-person hiring drive, which was widely read as IPO preparation. Large private rounds at elevated valuations tend to delay listings rather than accelerate them.

How does WHOOP's $440 per member revenue compare to Garmin's?
WHOOP’s $1.1 billion run rate across 2.5 million members implies approximately $440 per member annually. Garmin does not publish an equivalent active user figure, but its per-customer revenue is almost certainly far lower. The subscription model justifies some of that premium, replacing a single hardware transaction with recurring annual income.

Take Out

WHOOP reported 2025 bookings growth of 103 per cent year-on-year, a run rate of $1.1 billion, and cash flow positive operations. With Polar’s Loop band and Amazfit Helio in the market, and Garmin’s CIRQA band imminent, the window in which WHOOP operates without serious competition is closing. The public markets will eventually provide the honest answer on valuation.

The valuation only makes sense if WHOOP becomes a genuine healthcare platform — integrating continuous physiological data with clinical diagnostics and preventive medicine. Abbott and Mayo Clinic joining the funding round suggests that ambition is at least credible. It is also a long way from being realised, which is precisely why an IPO is unlikely in the near future.

For full context on WHOOP hardware, accuracy, and competitive position, see the WHOOP hub.

For full context on WHOOP hardware, accuracy, and competitive position, see the WHOOP hub.

Last Updated on 29 June 2026 by the5krunner

the5krunner

tfk is the founder and author of the5krunner, an independent endurance sports technology publication. With 20 years of hands-on testing of GPS watches and wearables, and competing in triathlons at an international age-group level, tfk provides in-depth expert analysis of fitness technology for serious athletes and endurance sport competitors. ID